Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
Board Certification:
Faculty Rank: Professor
Medical or Graduate Education:
Loyola University Chicago Stritch School of Medicine
Residency:
Boston University - Surgery
Fellowship:
National Cancer Institute - Surgical Oncology
Clinical Expertise:
Cancer surgery, skin
Melanoma
Sentinel lymph node biopsy
Soft tissue tumors
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Vaccines for melanoma and renal cell carcinoma. TroVax vaccine therapy for renal cell carcinoma. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. An association between corticosteroid use and melanoma recurrence: a case report and review of the literature. Vaccines for colorectal cancer and renal cell carcinoma. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. Statistical methods on detecting differentially expressed genes for RNA-seq data. Single-incision laparoscopic surgery for intra-abdominal metastatic melanoma. An update on TroVax for the treatment of progressive castration-resistant prostate cancer. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma Herpes simplex virus oncolytic vaccine therapy in melanoma Imaging the immune response to monitor tumor immunotherapy Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma Gene therapy for antitumor vaccination Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
To watch a brief video of Howard L. Kaufman, MD, click the play button at the lower left corner of the video frame below. (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
View Transcript I think this is a really exciting time to be a cancer physician, because we’ve never had more new options for patients. And so this spans the realm from preventing the cancers in the first place, to identifying them at earlier and earlier stages, to developing new treatments that are more effective. And what we often do with our patients is — once we’ve cured them of their cancer, we know that they’re still at a high risk for other problems in the future. And we try to really take care of them, and get them into an established prevention and screening program, so that if things progress in any way that we catch them early, and we can intervene at a time when we can be more effective.
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}